Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register
Authors' conclusion
We did not find differences in the risk of incident cancer in patients with rheumatic diseases and a previous malignancy between TNFi and other b/tsDMARDs.
Study context
- Population
- Patients with rheumatic diseases and a previous malignancy treated with b/tsDMARDs, BIOBADASER 3.0 up to 2021from 9,129 in BIOBADASER 3.0
- Participants
- 352 patients
- Exposure
- Other b/tsDMARDs vs TNFi
- Outcome
- Incident cancer (new primary, local recurrence or metastases) during drug exposure, rate per 1,000 PY
Methodological detailsregister-based (BIOBADASER 3.0)
- Register-based (BIOBADASER 3.0)
Main finding
As reported in the abstract
Adjusted rate of incident cancer vs TNFi
Each group vs TNFiAdjusted rate ratio (95 % CI)
JAKi
0.5(0.2–1.7)
anti-CD20
0.4(0.1–1)
anti-IL6
1.1(0.5–2.4)
anti-CTLA-4
1.5(0.7–3.1)
anti-IL17
0.7(0.2–2.4)
Observational data: associations, not effects.
Further findings
Rate of incident malignancy by group (events/1000 PY) · range across groups
Overall incident malignancies
- Incident malignancies (28 solid, 18 non-melanoma skin cancers, 1 melanoma)
- 47
- Overall rate, events/1,000 patients-year (PY)
- 47.4 (95 % CI 35.6-63.1)
Original publication
Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register. Semin Arthritis Rheum. Published 9 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →